Monash IVF Profit Slides on Higher Costs Despite Meeting Guidance

The latest update is out from Monash IVF Group Ltd ( (AU:MVF) ).

Monash IVF Group reported half-year 2026 revenue of $137.9 million, down 1.8% year-on-year, with underlying EBITDA falling 15.3% to $30.2 million and underlying net profit dropping 34% to $10.4 million, albeit at the upper end of previously updated guidance. Statutory net profit slumped 57.9% to $7.2 million as margins were pressured by higher costs, including investment in an enhanced patient management system and additional professional services, and the group withheld an interim dividend after paying a final dividend in October 2024.

The company highlighted several non-recurring or specific items, such as commissioning costs, class action, restructuring and acquisition-related items, SaaS and other technology expenses, and incident-related professional service costs, which materially affected the gap between statutory and underlying earnings. Net tangible assets per share remained negative, though modestly improved to negative 8.42 cents, and contributions from associates were minimal, underscoring a period of subdued profitability and continued operational and systems investment for the fertility services provider.

The most recent analyst rating on (AU:MVF) stock is a Buy with a A$0.77 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.

More about Monash IVF Group Ltd

Monash IVF Group Limited is a specialist healthcare provider focused on fertility services and assisted reproductive technologies. The group operates clinics and related reproductive health businesses, primarily serving patients seeking in vitro fertilisation and associated treatments in its key markets.

Average Trading Volume: 993,165

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$272.7M

See more insights into MVF stock on TipRanks’ Stock Analysis page.